CML

(redirected from Chronic myelogenous leukemia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

CML

Capital Market Line

In the capital asset pricing model, a line that plots the extra return an investor expects for each change in the level of risk. Rational investors expect higher returns for riskier assets and the capital market line shows this graphically. A portfolio that accurately reflects the capital market line is considered a Markowitz efficient portfolio. The slope of the capital market line is a calculation of the equilibrium market price of risk. See also: Beta.
References in periodicals archive ?
A new approach to treatment of Chronic Myelogenous Leukemia (CML) is to directly inhibit the molecular cause of the disease that is, using a protein-tyrosine kinase inhibitor that inhibits the bcr-abl, tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Ph chromosome translocation abnormality.
Chronic myelogenous leukemia (CML): clonal hematopoietic stem cell disorder accounting for 15%--20% of all cases of adult leukemia
Despite imatinib's success against chronic myelogenous leukemia, recent studies have found that the drug loses its effectiveness in about one-fifth of patients (SN: 6/17/06, p.
Reversible respiratory failure due to intravascular leukostasis in chronic myelogenous leukemia.
GlobalData estimates that the global Chronic Myelogenous Leukemia (CML) therapeutics market was valued at $1,089m in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 24% to reach $3,246m in 2010.
The approval was based on results from BFORE (Bosutinib trial in First line chrOnic myelogenous leukemia tREatment), a randomized multicenter, multinational, open-label Phase 3 study which showed BOSULIF 400 mg was associated with a significantly higher rate of patients achieving major molecular response (MMR) at 12 months (47.
Granulocytic sarcoma may be seen in multiple clinical scenarios: as a precursor of acute myelogenous leukemia in nonleukemic patients, as a herald ofimpendingblast crisis in chronic myelogenous leukemia, as a leukemic transformation of myelodysplastic disease, and as a distinct tissue manifestation in patients already diagnosed with acute myelogenous leukemia.
The immunizing peptide was derived from proteinase 3, a protein that is overexpressed on the surface of leukemia cells in patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS).
That changed when other scientists showed that the drug imatinib mesylate, or Gleevec, can thwart chronic myelogenous leukemia in animals and people by inhibiting another mutant tyrosine kinase (SN: 12/11/99, p.
The once-a-day-pill Glivec was used on 83 patients, including two San Fernando Valley residents, at the University of California, Los Angeles, in the first phase of chronic myelogenous leukemia, which strikes more than 10,000 people worldwide each year.
It is important to note clonal evolution (ie, additional numerical or structural chromosomal abnormalities) in patients with chronic myelogenous leukemia because 50% of patients enter an accelerated phase after about 3 years (Figure 2).

Full browser ?